“In a recent study, yet another standard treatment for cancer has been potentiated by cannabinoid agonists. Thisisthethirdchemotherapymedication I am aware of, where cannabinoid enhances the effects. Oncologists, who already know the benefit of cannabis for chemo side effects, need to continue to explore the potential to actually treat cancer.”
-
Dr. David Hepburn
Osteosarcoma
is the most common primary malignant tumor of bone in children and adolescents.
Bortezomib (BTZ) is an approved anticancer drug, classified as a selective
reversible inhibitor of the ubiquitin-dependent proteasome system, that leads
to cancer cell cycle arrest and apoptosis reducing the invasion ability of
Osteosarcoma cells in vitro.
Recently
BTZ has been evaluated in combination with Cannabinoids targeting CB1 receptor,
demonstrating a promising synergic effect.
Read
full article here:
0 comments:
Post a Comment